Related Experiment Video
Updated: Sep 13, 2025
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Clinical features, treatment and outcomes of dabrafenib-associated uveitis
Jieqiong Liu1, Wei Sun2, Chunjiang Wang3,4
1Department of Hematology and Oncology, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, 410005, Hunan, China.
Background:
To explore the clinical characteristics of dabrafenib-associated uveitis and provide a basis for diagnosis and treatment.
Methods:
The database was retrieved to collect reports of dabrafenib-associated uveitis and clinical data were collected for retrospective analysis.
Results:
Twenty-six patients were included in the study, with a median age of 56 years (range 30, 75). The onset time of uveitis was 3 months (range 0.75, 96) after administration. The types of uveitis were pan-uveitis (38.5%), anterior uveitis (34.6%), posterior uveitis (15.4%), and intermediate uveitis (3.8%). Fifty percent of the patients were Vogt-Koyanagi-Harada disease-like uveitis. After discontinuation of dabrafenib and treatment with topical and systemic steroids, the symptoms of uveitis improved in all patients.
Conclusion:
Patients are advised to have regular ophthalmology examinations during the use of dabrafenib. Timely administration of systemic or local corticosteroid treatment can significantly improve the symptoms of patients.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
01:25Glaucoma: Overview
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF